Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
Celcuity (NASDAQ: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025 after market close.
Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the call via phone (domestic: 1-800-717-1738, international: 1-646-307-1865) or through a live webcast. A replay will be available on Celcuity's website after the event.
Celcuity (NASDAQ: CELC), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie oncologiche mirate, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per gioved矛 14 agosto 2025 dopo la chiusura del mercato.
La direzione terr脿 una webcast e una conference call alle 16:30 ora della costa orientale per discutere i risultati e fornire un aggiornamento aziendale. Gli investitori potranno partecipare alla chiamata tramite telefono (nazionale: 1-800-717-1738, internazionale: 1-646-307-1865) o seguendo la diretta webcast. Una registrazione sar脿 disponibile sul sito web di Celcuity dopo l'evento.
Celcuity (NASDAQ: CELC), una empresa biotecnol贸gica en etapa cl铆nica centrada en el desarrollo de terapias oncol贸gicas dirigidas, ha programado la publicaci贸n de sus resultados financieros del segundo trimestre de 2025 para el jueves 14 de agosto de 2025 despu茅s del cierre del mercado.
La direcci贸n realizar谩 una webcast y una conferencia telef贸nica a las 4:30 p.m., hora del Este para discutir los resultados y proporcionar una actualizaci贸n corporativa. Los inversores pueden acceder a la llamada por tel茅fono (dom茅stico: 1-800-717-1738, internacional: 1-646-307-1865) o a trav茅s de una transmisi贸n en vivo. Una repetici贸n estar谩 disponible en el sitio web de Celcuity despu茅s del evento.
Celcuity (NASDAQ: CELC)電� 響滌爜 頃晹 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 靸濍獏瓿淀暀 須岇偓搿�, 2025雲� 2攵勱赴 鞛 瓴瓣臣 氚滍憸毳� 2025雲� 8鞗� 14鞚� 氇╈殧鞚� 鞛� 毵堦皭 頉勲 鞓堨爼頄堨姷雼堧嫟.
瓴届榿歆勋潃 霃欕秬 響滌鞁� 鞓ろ泟 4鞁� 30攵�鞐� 鞗轨簮鞀ろ姼 氚� 旎嵓霟办姢 旖滌潉 臧滌禍頃橃棳 瓴瓣臣毳� 雲检潣頃橁碃 須岇偓 順勴櫓鞚� 鞐呺嵃鞚错姼頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� 鞝勴檾(甑偞: 1-800-717-1738, 甑牅: 1-646-307-1865) 霕愲姅 鞁れ嫓臧� 鞗轨簮鞀ろ姼毳� 韱淀暣 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 頄夓偓臧� 雭濍倻 頉� Celcuity 鞗轨偓鞚错姼鞐愳劀 雼れ嫓氤搓赴 靹滊箘鞀るゼ 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
Celcuity (NASDAQ : CELC), une entreprise biotechnologique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies oncologiques cibl茅es, a programm茅 la publication de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le jeudi 14 ao没t 2025 apr猫s la cl么ture du march茅.
La direction organisera une webdiffusion et une conf茅rence t茅l茅phonique 脿 16h30, heure de l'Est pour discuter des r茅sultats et fournir une mise 脿 jour de l'entreprise. Les investisseurs peuvent acc茅der 脿 l'appel par t茅l茅phone (domestique : 1-800-717-1738, international : 1-646-307-1865) ou via une webdiffusion en direct. Une rediffusion sera disponible sur le site web de Celcuity apr猫s l'茅v茅nement.
Celcuity (NASDAQ: CELC), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf zielgerichtete Krebstherapien spezialisiert hat, hat die Ver枚ffentlichung der Finanzergebnisse 蹿眉谤 das zweite Quartal 2025 蹿眉谤 Donnerstag, den 14. August 2025 nach B枚rsenschluss geplant.
Das Management wird um 16:30 Uhr Eastern Time eine Webcast- und Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren k枚nnen 眉ber Telefon (national: 1-800-717-1738, international: 1-646-307-1865) oder einen Live-Webcast teilnehmen. Eine Aufzeichnung wird nach der Veranstaltung auf der Celcuity-Website verf眉gbar sein.
- None.
- None.
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: . A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K伪, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity鈥檚 active clinical trials can be found at听. Celcuity is headquartered in Minneapolis.听Further information about Celcuity can be found at听. Follow us on听听补苍诲听.
Contacts:听
Celcuity Inc.听
Brian Sullivan, 听
Vicky Hahne, 听
(763) 392-0123听
ICR Healthcare
Patti Bank, 听
(415) 513-1284
FAQ
When will Celcuity (CELC) release Q2 2025 earnings?
How can investors access Celcuity's Q2 2025 earnings call?
What is Celcuity's main business focus?
Will there be a replay available of Celcuity's Q2 2025 earnings call?
